news center

The second phase production workshop of the company has been built and is undergoing equipment debugging. It will be put into operation by the end of this year. The new production line will adopt the folding countercurrent extraction technology, which has a higher degree of automation and can greatly save costs. "On June 15th, at Hunan Xingchen Biotechnology Co., Ltd., the production plant director Mr. Gui Jianguo was telling employees about the company's next development prospects.

In 2014, due to the limited height of the factory building, we broke tradition and independently improved the technology. It not only solved the problem of limited height of the factory building and equipment placement, but also greatly improved production efficiency.

We can produce about 40 tons of Artemisinin every year, with an annual output value of over USD 8.33 million. Since 2010, our company has invested heavily in promoting the planting of new varieties of Artemisia Annua. We have established Yongzhou Xingchen, Daoxian Chenxiang, and Xintian Wanfu Artemisia Annua farmers' professional cooperatives in Lengshuitan Dist., DaoxianCounty, and Xintian County respectively, and established our own planting bases. The annual planting area of Artemisia Annua is 2333.33 hectares, "said Mr.Gui Jianguo.

Artemisinin is a sesquiterpene lactone compound extracted from the Asteraceae plant Artemisia Annua, which is a specific drug for treating malaria caused by Plasmodium falciparum. Yongzhou is located in the upper reaches of the XiangJiang River, with mountainous terrain and unpolluted air and water, making it an ideal place for the cultivation of Chinese herbal medicine. Due to its unique climate and geographical location, planting Artemisia Annua in Yongzhou results in relatively high yields and Artemisinin content compared to other regions in China. Yongzhou has now become one of the best areas for Artemisia Annua cultivation in China.

Hunan Xingchen Biotechnology Co., Ltd. is an outward oriented enterprise engaged in the cultivation, planting, acquisition, processing, and sales of Chinese herbal seedlings. Our main product is Artemisinin, which is popular in overseas markets such as Europe, America, India, and Africa. Our company has been committed to technological research and development for many years, gaining an advantage in the Artemisinin market. Our company currently has 73 employees and a technology research and development team covering multiple specialties such as pharmacy, traditional Chinese medicine, biotechnology, and mechanical manufacturing. Our company has an advanced Artemisinin extraction and concentration production line in China and passed the Global Fund EHS certification in the year of 2017.

At present, our company has one invention patent and three utility model patents, and is one of the leading plant extraction enterprises in Yongzhou City.

In 2014, we became a member unit of Hunan Plant Extraction Association. In 2016, the registered trademark "Huafeng Xingchen" was rated as a well-known trademark in Yongzhou City. In 2017, it was recognized as a small giant enterprise in Hunan Province. In 2018, it was recognized as a provincial-level agricultural industrialization leading enterprise and a provincial-level high-tech enterprise.

In 2019, our company's Artemisinin sales accounted for over 20% of the national Artemisinin sub market and over 18% of the global market, ranking among the top three Artemisinin manufacturers in China. Our company's investment of USD 6.944 million to build the "Continuous Reflux Extraction of Artemisinin Construction Project" has been listed as a major product innovation project in Yongzhou City. After the completion of the project, our company's annual production and sales revenue of Artemisinin will reach a higher level.